<i>Astragalus polysaccharide</i> alleviates neuropathology and cognitive deficits by modulating gut microbiota and neuroinflammation in an Alzheimer's disease model.
Overview
- Department of Geriatric, The People’s Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, China
- Department of Neurology, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital,Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China
- The Affiliated People’s Hospital, College of Integrative Medicine, Fujian-Hong Kong-Macau-Taiwan Collaborative Laboratory for the Inheritance and Innovation of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China
- Department of Neurology and Geriatrics, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, China
- Fujian Key Laboratory of Molecular Neurology, Fujian Key Laboratory of Vascular Aging, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China
Abstract
Background: Emerging evidence indicates that the neuroprotective effects of Astragalus polysaccharides (APS), an extract compound and bioactive constituent derived from traditional Chinese herbs, may be relevant to an effective prescription for delaying progression of Alzheimer’s disease (AD), yet the underlying mechanisms remain to be fully elucidated. This study aimed to investigate the therapeutic efficacy of APS in alleviating cognitive impairment and neuropathology in 5×FAD transgenic mice, with a specific focus on the regulatory role of the gut-brain axis.
Methods: Male 5×FAD mice were orally administered APS (200 mg/
Results: APS administration was well-tolerated throughout the study period, with no overt toxic effects observed. Moreover, APS administration significantly ameliorated spatial learning and memory deficits in 5×FAD mice. Mechanistically, APS treatment reduced Aβ plaque burden, restored synaptic protein expression (PSD-95 and Syntaxin), and attenuated microglia-mediated neuroinflammation by suppressing pro-inflammatory cytokines (IL-6, TNF-α) and upregulating TREM2. Microbiome analysis revealed that APS reshaped gut microbial diversity and composition, enriching beneficial taxa such as Lactobacillus. Metabolomics indicated a partial restoration of amino acid metabolism. Notably, FMT from APS-treated donors successfully reproduced the cognitive improvements and anti-inflammatory effects in recipient mice.
Conclusion: These findings demonstrate that APS alleviates cognitive deficits and AD-like pathology, partially through remodeling gut microbiota and modulating the gut-brain axis. APS represents a promising natural compound-based therapeutic candidate for managing cognitive decline associated with Alzheimer’s disease.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- figshare:33032705, at figshare; found in “Data availability statement”
Data availability statement
The data presented in the study are deposited in the figshare repository, https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, pages, dates, 11 authors, 6 keywords, 1 funder, 69 references.
Cite
This paper
Cui, X., Wei, Z., Wang, Q., Du, S., Lin, Z., Chen, Z., Zhang, J., Li, C., Tang, L., Dai, X., & He, W. (2026). &
BibTeX
@article{cui2026lt,
author = {Cui, Xiaoli and Wei, Zhen and Wang, Qingshui and Du, Sizhe and Lin, Zi and Chen, Zibo and Zhang, Jie and Li, Chao and Tang, Lanfang and Dai, Xiaoman and He, Weidong},
title = {{\&
journal = {Frontiers in pharmacology},
year = {2026},
month = aug,
volume = {17},
pages = {1830927},
publisher = {Frontiers Media SA},
issn = {1663-9812},
doi = {10.3389/
url = {https://
pmid = {42676794},
pmcid = {PMC13527023}
}
RIS
TY - JOUR
AU - Cui, Xiaoli
AU - Wei, Zhen
AU - Wang, Qingshui
AU - Du, Sizhe
AU - Lin, Zi
AU - Chen, Zibo
AU - Zhang, Jie
AU - Li, Chao
AU - Tang, Lanfang
AU - Dai, Xiaoman
AU - He, Weidong
TI - &
T2 - Frontiers in pharmacology
J2 - Front Pharmacol
PY - 2026
DA - 2026/
VL - 17
SP - 1830927
SN - 1663-9812
PB - Frontiers Media SA
DO - 10.3389/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.3389/
"type": "article-journal",
"title": "&
"container-title": "Frontiers in pharmacology",
"author": [
{
"family": "Cui",
"given": "Xiaoli"
},
{
"family": "Wei",
"given": "Zhen"
},
{
"family": "Wang",
"given": "Qingshui"
},
{
"family": "Du",
"given": "Sizhe"
},
{
"family": "Lin",
"given": "Zi"
},
{
"family": "Chen",
"given": "Zibo"
},
{
"family": "Zhang",
"given": "Jie"
},
{
"family": "Li",
"given": "Chao"
},
{
"family": "Tang",
"given": "Lanfang"
},
{
"family": "Dai",
"given": "Xiaoman"
},
{
"family": "He",
"given": "Weidong"
}
],
"container-title-short":
"volume": "17",
"page": "1830927",
"DOI": "10.3389/
"PMID": "42676794",
"PMCID": "PMC13527023",
"ISSN": "1663-9812",
"publisher": "Frontiers Media SA",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
8,
17
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1038/s41467-025-64503-x
- Stage-specific roles of clonally expanded CD8&
lt;sup& gt;+& lt;/ sup& gt; T cells in regulating amyloid pathology in Alzheimer's disease models. Journal: Nature communicationsIn common: Alzheimer's / dementia, mouse, cellular / molecular, 4 references - [2] doi:10.1016/j.celrep.2025.116109
- Amyloid-β-driven Alzheimer's disease reshapes the colonic immune system in mice.Journal: Cell reportsIn common: Alzheimer's / dementia, mouse, cellular / molecular, 3 references
- [3] doi:10.1038/s41467-026-68937-9
- Gut microbiota-dependent 24-hydroxycholesterol metabolism contributes to capsaicin-induced amelioration of Alzheimer's disease-like pathology in mice.Journal: Nature communicationsIn common: Alzheimer's / dementia, mouse, cellular / molecular, 3 references
- [4] doi:10.1186/s12967-025-06937-x
- Integrating imaging and omics for enhanced subtyping of mild cognitive impairment associated with Alzheimer's disease.Journal: Journal of translational medicineIn common: Alzheimer's / dementia, genetics / omics, 3 references
- [5] doi:10.1016/j.xcrm.2024.101669
- Integrative proteomics identifies a conserved Aβ amyloid responsome, novel plaque proteins, and pathology modifiers in Alzheimer's disease.Journal: Cell reports. MedicineIn common: Alzheimer's / dementia, genetics / omics, mouse, 1 other category, 3 references
- [6] doi:10.1080/19490976.2024.2302310 [code]
- Gut microbiota-driven metabolic alterations reveal gut-brain communication in Alzheimer's disease model mice.Journal: Gut microbesIn common: Alzheimer's / dementia, genetics / omics, mouse, 2 references
- [7] doi:10.1186/s13024-022-00588-y
- TREM2 dependent and independent functions of microglia in Alzheimer's disease.Journal: Molecular neurodegenerationIn common: Alzheimer's / dementia, mouse, cellular / molecular, 3 references
- [8] doi:10.1186/s12967-026-07862-3
- Overexpression of PGRMC2 in astrocytes improved cognitive function in a mouse model of Alzheimer's disease by modulating neuroinflammation.Journal: Journal of translational medicineIn common: Alzheimer's / dementia, mouse, 2 references
- [9] doi:10.1186/s13024-024-00712-0
- Updates on mouse models of Alzheimer's disease.Journal: Molecular neurodegenerationIn common: Alzheimer's / dementia, mouse, cellular / molecular, 3 references
- [10] doi:10.1126/sciadv.aej4603
- BCG vaccination mitigates tau pathology and restores cognitive function in PS19 mice.Journal: Science advancesIn common: Alzheimer's / dementia, mouse, 3 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
